Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation reports developments tied to its role as a diversified healthcare services company and major pharmaceutical distributor. Company news commonly covers fiscal results and guidance, dividend declarations, capital allocation, share repurchase activity, and updates across core distribution, oncology and multispecialty, biopharma services, pharmacy technology, and medical-surgical product categories.
McKesson updates also include portfolio actions and governance changes. Recent company materials document the completed divestiture of its Norwegian retail and distribution businesses, marking its exit from European operations, alongside recurring communications about earnings events, healthcare conferences, and leadership succession matters.
McKesson (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings release, financial tables and slide presentation.
McKesson has announced its fiscal 2025 second quarter financial results. The detailed results are accessible on McKesson’s Investor Relations website. Additionally, the company has raised its full-year adjusted EPS guidance.
McKesson will host a live webcast of the earnings conference call on Wednesday, November 6th at 4:30 PM ET. The webcast and related materials, including the press release, financial tables, and slide presentation, will be available on McKesson's Investor Relations website. Further information about upcoming investor events is also available on the same site.
McKesson (NYSE:MCK) announced that its Board of Directors has declared a regular quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of December 2, 2024, with the payment scheduled for January 2, 2025.
McKesson (NYSE: MCK) has announced the release date for its second quarter fiscal 2025 financial results. The company will unveil its earnings after market close on Wednesday, November 6, 2024. Following the release, McKesson will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time.
Investors can access the live webcast on McKesson's Investor Relations website at http://investor.mckesson.com. The website will also provide access to the company's earnings release, financial tables, and slide presentation. This announcement allows shareholders and interested parties to mark their calendars for McKesson's upcoming financial disclosure and discussion of its quarterly performance.
McKesson (NYSE: MCK) has announced the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This strategic move aligns with McKesson's enterprise strategy to focus on growing its oncology and biopharma services platforms. The transaction allows McKesson to streamline its business and prioritize investments in key growth areas.
Despite this divestiture, McKesson remains committed to its Canadian distribution and biopharma businesses. The company believes that Rexall and Well.ca will benefit from Birch Hill's resources and capital to expand their services across Canada. McKesson Canada intends to continue as a wholesale distribution supplier to both businesses after the transaction closes.
McKesson (NYSE: MCK) has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, (Core Ventures) for approximately $2.49 billion in cash. This acquisition will give McKesson about 70% ownership of Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute (FCS).
Following the transaction, FCS will join The US Oncology Network, part of McKesson's Oncology platform. FCS, with over 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida, will remain independently owned. This strategic move aims to enhance McKesson's integrated oncology platform and advance community-based oncology care.
McKesson (NYSE: MCK) has released its fiscal 2025 first quarter financial results, which are now available on the company's Investor Relations website. McKesson will host a live webcast of the earnings conference call for investors on Wednesday, August 7th at 4:30 PM ET to review these results. The audio webcast, earnings press release, financial tables, and slide presentation will be accessible on McKesson's Investor Relations website. This platform also provides information about upcoming events for the investor community.
McKesson (NYSE:MCK) has announced a 15% increase in its quarterly dividend to $0.71 per share, up from $0.62 in the previous quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. This marks McKesson's eighth consecutive annual dividend increase, reflecting the company's confidence in its business fundamentals and financial strength. CEO Brian Tyler emphasized McKesson's commitment to a disciplined capital deployment strategy, focusing on growth and shareholder value creation. The dividend hike underscores the company's strong balance sheet and robust free cash flow generation capabilities.
McKesson (NYSE: MCK) is set to release its first quarter fiscal 2025 financial results on August 7, 2024, after market close. A live webcast of the earnings conference call will be held at 4:30 PM Eastern Time, available on McKesson’s Investor Relations website. The webcast will cover financial results, including earnings release, financial tables, and a slide presentation.
McKesson announced the election of Dr. Deborah Dunsire to its board of directors, effective June 3, 2024. Dr. Dunsire, with over 30 years of experience in the biopharmaceutical and oncology sectors, will also serve on the Compensation and Talent Committee and Finance Committee. She recently retired as CEO of H. Lundbeck A/S and has held leadership roles at XTuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium: The Takeda Oncology Company.
Meanwhile, current board members Linda Mantia and Susan Salka will not stand for re-election at the 2024 Annual Meeting of Shareholders. The board size will reduce to 11 members, 10 of whom will be independent. McKesson's board chair, Donald Knauss, expressed gratitude for their contributions.